TC
INO icon

TFS Capital’s Inovio Pharmaceuticals INO Stock Holding History

TFS Capital’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-26,977
Closed -$2.17M – 1043
2015
Q4 		$2.17M Buy
+26,977
New +$2.15M 0.23% 148

Other funds holding INO

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TFS Capital's INO Position: Q1 2016 in Review

TFS Capital sold out of Inovio Pharmaceuticals (INO) in Q1 2016, closing a stake of 26,977 shares — an estimated $2.17M sold.

TFS Capital first reported a position in INO in Q4 2015 and held it in 1 quarter. The position peaked at $2.17M in Q4 2015. 115 funds tracked by Wall St. Rank hold INO as of Q1 2016.

  • TFS Capital reported no remaining Inovio Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • TFS Capital sold 26,977 Inovio Pharmaceuticals shares in Q1 2016, an estimated $2.17M.
  • TFS Capital first reported a position in Inovio Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • TFS Capital's Inovio Pharmaceuticals position peaked at $2.17M in Q4 2015.
  • 115 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2016.

Based on TFS Capital's 13F filing for Q1 2016, filed 10 May 2016.